We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Interim guidance and information on the law for healthcare professionals
Report examining issues relating to road safety and the use and prescription of medical cannabis.
The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use.
The therapeutic and medicinal benefits of cannabis-based products – a review of recent evidence.
What you need to know before you can place a medical device on the Great Britain market with a UKCA mark.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Advice for medical professionals to follow when assessing drivers with drug or alcohol misuse or dependence.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
What you need to do to place a medical device on the Great Britain, Northern Ireland and European Union (EU) markets.
Information about controlled drugs licences for companies that possess, manufacture, produce or supply controlled drugs in England, Wales or Scotland.
Guidance on manufacturing, importing, distributing and supplying specially manufactured or ordered products, including cannabis-based products for medicinal use in humans (CBPMs), known as 'specials'
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).